Genmab — August 2014
-
http://www.roche.com/investors/annual_reports.htm side 135. Rituxan op 4% som top selling drug. Gazyva ikke blandt de 20 bedst sælgende - det er imponerende at rtx kører derudaf endnu !
-
https://oasm.finanstilsynet.dk/dk/vismeddelelse.aspx?aid=44387ba2-18e4-4821-b384-8889a466f0ce short position i genmab af BlueCrest
-
BCML is licensed and regulated by the Guernsey Financial Services Commission ("GFSC") under the Protection of Investors (Bailiwick of Guernsey) Law, 1987 as amended to carry on controlled investment business in or from within the Bailiwick of Guernsey
-
Husk at stil spørgsmål tl Q&A i Genmab
-
Ser da godt ud nu. Over 230
-
Den short kan godt gå hen og blive dyr. Jeg forstår ikke timingen, Dara milestones, data og muligt på markedet om et år. En short nu er
risikabel -
De anonyme går til den, kan jo være short covering, men de skal rapportere det når de går under 0,5% senest dagen efter
-
-
https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=313915013&sourcecode=ddk utroligt Frank allerede er ude og gardere sig inden regnskabet overhovedet er kommet. Hvorfor får han så meget taletid hos Ritzau sammenlignet med bowers og novod. Franks track record er jo elendig
-
jojo, gad bare godt de også interviewede de andre og ikke kun ringede til FF hver gang. men kan være ritzau har en aftale med jyske bank
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind